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INTRODUCTION
sensilivity of these tests has increased, the need for laparoscopy to confirm the diagnosis has dccrcadscd.
In fact, with current techniques, cctpoic pregnancy can be diagnosed reliably without the need for laparoscopy.
Worldwide, there has been a marked increase in the absolute number and rate of ectopic pregnancy in the last two decades with an increase of four folds. In the USA, for instance, from 1970 to 1992. The incidence is increased with increasing age (4) . The rise can be attributed partly to an increase in certain risk factors and partly to improved diagnosis. Some Table I .
In 1956, Li & colleges were the first to report the effective use of mctholrcxalc (MTX) for the treatment of gcsiational trophoblastic diseases (5) .
Tanaka et al* 6 ' reported successful treatment of ectopic pregnancy with intramuscular mctholrcxalc in 1982. Sloval and Ling (7) described the one dose protocol.
Until late 90s experiences with the single-dose protocol has been described in the literature for more than 1500 cases with success rates ranging from 71% and 100% < s ' 12) . Despite this, use of mcthotrexatc remains somewhat controversial.
Women most likely to respond to mcthotrexatc treatment arc thought to be those with small masses, lower scrum concentrations of hCG and progesterone and the absence of blood in the peritoneal cavity. But it has been difficult to determine the true effect of those characteristics on success rates because of the small size of previous studies (13 ' ,4 ''5) • Did not desire surgical treatment. • Agree to weekly follow up until scrum concentration of hCG decreased to 15 mlU/ml or less.
OBJECTIVES
• No sonographic evidence of fetal heart activity.
• Did not have hepatic, hcmatologic or renal diseases (as evidenced by scrum aminolrasfcrasc concentration more than twice, the upper limit of WBC less than 15,000/mm, a platelet count of less than 100,000/ml or scrum crcatininc of more than 133mmol/l).
Exclusion criteria:
• Women with moderate to severe abdominal pain or adnexal tenderness.
• Mass size of more than 4.2 cm lmg/kgAVB).
Treatment success was defined as the achievement of a scrum hCG concentration of 15mIU/ml or less without the need for surgical intervention.
Women with scrum hCG concentrations of less than 3000 mlU/ml were discharged home 4 hrs after trcatmcnl with melholrexate, while ihose with concentrations above 3000 mlU/ml were kepi in the hospital until evidence of success i.e. decline in hCG concentrations by at least 15%.
Scrum hCG concentrations and progesterone were measured by Elcclrochcmilumincscncc immunoassay (ECLIA) using Elccsys 2010 laboratory machine.
The size of the gcslational mass was defined as its maximal diameter in any dimension as measured by cndovaginal ultrasonography. Ultrasonography was repealed on day 4 and day 7.
Hystcrosalpingography (HSG) was performed 3 months after the end of successful treatment.
There were 41 women with cctopic pregnancies diagnosed in MMCH during the period between
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In I rave nous melholrexate for ectopic 38 women were Saudi (92,7%) while the rest were non Saudi (7,3%). Table H (Table VI) .
Six patients (17.65%) required a second methotrexatc dose on day 7. The mean initial scrum hCG concentration of these six women was 4582.2 ± 2822.8 mlU/ml on Dl and 5729.7 ± 3240.0 mlU/ml
•on D7 and a scrum progesterone level of 13.827 ± 22.8 ng/ml (7.6, 60, 0.33, 3.2, 7.6 and 4.2). The mass size was not different from other treated patients 2.47 ± 0.92. In these patients, the resolution time of hCG levels was relatively longer (47.8 ±11.1 days) Table   VII .
No patients required more than 2 doses. In sixteen patients (47.1%), the scrum hCG concentration were elevated on day 4. In ten of them, the concentrations declined by more than 15% on day 7. Side effects to methotrexatc treatment were minimal. They were observed in one patient in the form of mild self-limiting diarrhea lasting for 16 hrs. (Table IX) shows that there is no statistical differences regarding age, parity and abortions.
In the current study, the mean initial serum -In a review of 23 studies (all from 1990 and earlier):
• 3% failure rate for hCG concentrations below 5000 mlU/ml.
• 37% failure rale for concentrations above 10,000 mlU/ml.
The authors concluded that scrum hCG concentrations abov 10,000 mlU/ml was a risk factor for failure * 4 l
Stikn cl a I treated 50 patients with methotrexale.
They concluded that those women with initial scrum hCG concentrations above 5000 mlU/ml had a greater probability o\ : requiring cither surgical intervention or multiple doses of mctholrcxalc* l8 \ Of interest was that non of the 11 patients m whom treatment was unsuccessful had an initial scrum hCG concentration above 3490 mlU/ml, This could be due to their inclusion criteria.
The size of the cctopic gestation mass is frequently used us exclusion criteria for methotrexale therapy.
Few data arc available. In 30 women treated, the success rale was 90% in those masses between 3.0 and 3.2 compared with 93% for masses of less than
The presence of fetal cardiac activity has also been considered as a contraindication for mcthotrcxate therapy although success rates have been reported when fetal heart activity was present in 88% ^' No. 
COST EFFECIVENESS
The The prognostic value of the proposed factors appears to be directly related to their association with scrum hCG concentration. These women should be well evaluated, and mcthotrcxatc is still a treatment option.
These results can be used to counsel women with cctopic pregnancies regarding the likelihood of successful treatment with single-dose intravenous mcthotrcxatc.
